Novartis Pharmaceuticals Canada Inc.
385 Bouchard Boulevard
Dorval
Quebec
H9S 1A9
Canada
Tel: 514-631-6775
38 articles about Novartis Pharmaceuticals Canada Inc.
-
Health Canada approves an extended indication for KISQALI® (ribociclib) in combination treatment
4/16/2020
Novartis Pharmaceuticals Canada Inc. is pleased to announce that KISQALI® is now indicated when used in combination for the treatment of women with hormone receptor -positive, human epidermal growth factor receptor 2 -negative advanced or metastatic breast cancer regardless of their menopause status and in combination with various approved hormonal treatment options.
-
Novartis receives Health Canada approval for Mayzent™ (siponimod) to treat secondary progressive multiple sclerosis with active disease
3/3/2020
Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved MayzentTM for the treatment of adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, to delay the progression of physical disability.
-
Women living with metastatic breast cancer in British Columbia now have public access to KISQALI®
10/23/2019
Novartis Pharmaceuticals Canada Inc. is pleased to announce that British Columbia will now reimburse KISQALI® for eligible patients in combination with an aromatase inhibitor under its provincial public drug program.
-
Addition of KISQALI® to drug plan in Quebec expands access to treatment for metastatic breast cancer
9/19/2019
Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer
-
Novartis Pharmaceuticals Canada Inc. Release: Canadians With Advanced Skin Cancer Share Their Disease Journey With Launch Of An Empowering Photo Series: Melanoma Through My Lens
8/17/2016
-
This Is An Amended Media Release Further To Novartis Pharmaceuticals Canada Inc.'s ("Novartis") Media Release Issued On January 7, 2015 For Fluad Pediatric
7/5/2016
-
Novartis Pharmaceuticals Canada Inc. Announces Results At 2014 American Thoracic Society International Conference For Once Daily Dual Bronchodilator Ultibro® Breezhaler® Versus Combination Therapy For COPD
5/21/2014
-
Novartis Pharmaceuticals Canada Inc. Release: Bexsero®: First Vaccine To Prevent Meningococcal Serogroup B (MenB) Now Available In Canada
2/26/2014
-
Novartis Pharmaceuticals Canada Inc. Receives Health Canada Approval For Ultibro Breezhaler ®, A Once-Daily Dual Bronchodilator For COPD
1/14/2014
-
Health Canada Approves Novartis Pharmaceuticals Canada Inc.'s Bexsero*, The First Vaccine Available To Prevent Meningococcal Serogroup B (MenB)(1,2)
12/9/2013
-
Novartis Pharmaceuticals Canada Inc. Release: New Study Confirms Seasonal Flu Vaccine Designed for Seniors Improved Protection Against Influenza?
11/5/2013
-
Novartis Pharmaceuticals Canada Inc. Continues to Build Its COPD Pipeline and Presents New Data on Investigational Once-Daily QVA149 at ERS
9/9/2013
-
Novartis Pharmaceuticals Canada Inc. Release: Now Available in Ontario, (Pr)SEEBRI* BREEZHALER*, a Long-Term Once-Daily Maintenance Treatment for Chronic Obstructive Pulmonary Disease (COPD)
9/3/2013
-
Novartis Pharmaceuticals Canada Inc. Resumes Seasonal Influenza Vaccine Distribution as Health Canada Lifts Suspension
11/1/2012
-
Novartis Pharmaceuticals Canada Inc. Release: Canadian Agency for Drugs and Technologies in Health (CADTH) Recommends Provincial and Publicly Funded Drug Plans Reimburse (Pr)Lucentis* to Treat Vision Loss Resulting From Diabetic Macular Edema (DME)
3/29/2012
-
Novartis Pharmaceuticals Canada Inc. Pulls Prexige From Canada on Safety Issues
10/4/2007
-
Health Canada Removes Novartis Pharmaceuticals Canada Inc.'s Cox-2 Drug Prexige from the Market over Liver Problems
10/4/2007
-
Novartis Pharmaceuticals Canada Inc. Selects Skura Corporation To Partner In An Innovative Initiative For The Novartis Sales Force
10/11/2006